BEACON TOPCO, INC. (CLYD)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-30 | Phase3 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
Active Clinical Trials (12)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06275204 | H. Pylori Screen-and-treat Study in a Population of Young Adults | OTHER | Recruiting | 6,800 |
| NCT07110376 | Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease | OTHER | Recruiting | 10 |
| NCT07476313 | Validation and Usability Study of the SleepView+ Home Sleep Testing System for the Evaluation of Moderate to Severe Obst... | OTHER | Enrolling By Invitation | 200 |
| NCT03862911 | Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer | OTHER | Active Not Recruiting | 330 |
| NCT07401550 | Assessment and Prediction of Cardiovascular Health and Disease Risk Using Wearable Biometrics. | OTHER | Recruiting | 100 |
| NCT07290088 | Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients | PHASE3 | Recruiting | 52 |
| NCT04850118 | A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XL... | PHASE3 | Active Not Recruiting | 85 |
| NCT06333249 | A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SK... | PHASE2 | Active Not Recruiting | 14 |
| NCT02935517 | Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) | PHASE2 | Active Not Recruiting | 24 |
| NCT07174726 | A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Partic... | PHASE2 | Active Not Recruiting | 10 |
| NCT02599922 | Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial) | PHASE2 | Active Not Recruiting | 32 |
| NCT06275620 | A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations... | PHASE2 | Enrolling By Invitation | 24 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.